Effects of the intake of non-live Bifidobacterium bifidum on the faecal IgA of full-term infants: a double-blind, randomised, placebo-controlled study
- PMID: 34631331
- PMCID: PMC8484005
- DOI: 10.12938/bmfh.2021-018
Effects of the intake of non-live Bifidobacterium bifidum on the faecal IgA of full-term infants: a double-blind, randomised, placebo-controlled study
Abstract
Bifidobacterium bifidum OLB6378 (OLB6378) was selected as a strain that enhances the production of secretory immunoglobulin A (IgA) in vitro. This ability of non-live OLB6378 has been shown by a clinical trial in preterm infants. In the present study, we examined whether non-live OLB6378 also enhances the production of secretory IgA, even in full-term infants. One hundred full-term infants were allocated to receive formula with (BbF group, 49 infants) or without non-live OLB6378 (PF group, 51 infants). Breastfeeding was prioritised, so infant formula was used for infants with breastfeeding difficulties. The intervention was initiated by five days of age. The faecal IgA concentration and OLB6378 level were determined at one, two, four, and eight weeks of age. Faecal IgA in the BbF group (1.04 ± 0.47 mg/g of faeces, n=45) was significantly higher than that in the PF group (0.85 ± 0.42 mg/g of faeces, n=49) at four weeks of age (p=0.047). OLB6378 was not detected in faeces at any age. This indicated that production of secretory IgA in full-term infants may also be enhanced by non-live OLB6378 intake.
Keywords: breastfeeding; infant formula; newborn; probiotics.
©2021 BMFH Press.
Figures




Similar articles
-
Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study.Nutrients. 2017 Feb 26;9(3):195. doi: 10.3390/nu9030195. Nutrients. 2017. PMID: 28245626 Free PMC article.
-
Strain-specific identification of Bifidobacterium bifidum OLB6378 by PCR.Biosci Biotechnol Biochem. 2013;77(3):572-6. doi: 10.1271/bbb.120803. Epub 2013 Mar 7. Biosci Biotechnol Biochem. 2013. PMID: 23470759
-
Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial.JPEN J Parenter Enteral Nutr. 2012 Jan;36(1 Suppl):106S-17S. doi: 10.1177/0148607111430817. JPEN J Parenter Enteral Nutr. 2012. PMID: 22237870 Clinical Trial.
-
Dilute versus full-strength formula in exclusively formula-fed preterm or low birth weight infants.Cochrane Database Syst Rev. 2019 Jun 27;6(6):CD007263. doi: 10.1002/14651858.CD007263.pub3. Cochrane Database Syst Rev. 2019. PMID: 31246272 Free PMC article.
-
Nutrition, growth, and allergic diseases among very preterm infants after hospital discharge.Dan Med J. 2013 Feb;60(2):B4588. Dan Med J. 2013. PMID: 23461996 Review.
Cited by
-
Microbiota, IgA and Multiple Sclerosis.Microorganisms. 2022 Mar 14;10(3):617. doi: 10.3390/microorganisms10030617. Microorganisms. 2022. PMID: 35336190 Free PMC article. Review.
-
Bifidobacterium longum Subsp. infantis Promotes IgA Level of Growing Mice in a Strain-Specific and Intestinal Niche-Dependent Manner.Nutrients. 2024 Apr 12;16(8):1148. doi: 10.3390/nu16081148. Nutrients. 2024. PMID: 38674840 Free PMC article.
References
-
- Yasui H, Nagaoka N, Mike A, Hayakawa K, Ohwaki M. 1992. Detection of Bifidobacterium strains that induce large quantities of IgA. Microb Ecol Health Dis 5: 155–162.
-
- Makioka Y, Tsukahara T, Ijichi T, Inoue R. 2018. Oral supplementation of Bifidobacterium longum strain BR-108 alters cecal microbiota by stimulating gut immune system in mice irrespectively of viability. Biosci Biotechnol Biochem 82: 1180–1187. - PubMed
-
- Terahara M. 2017. Challenge of development of probiotics for neonates. Milk Science 66: 247–253 (in Japanese).
LinkOut - more resources
Full Text Sources
Miscellaneous